FoundationOneHeme (Foundation Medicine Inc.)January 18, 2018
Molecular diagnostic testing for hematologic malignancies and sarcomas currently involves the use of multiple assays, each designed to detect a specific type of genomic alteration. The detection of these alterations may help with determining prognosis or driving treatment. It has been suggested that a comprehensive test that simultaneously assesses for these different types of genomic alterations may enhance diagnostic capabilities and offer increased opportunities for targeted therapy. This report reviews 1 such test, the FoundationOneHeme test.
If you have a Hayes login, click here to view the full report on the Knowledge Center.